The companion animal sector has been the main driver of growth for the global
animal health industry since the mid-1990s.This essential report analyses the
size and structure of the companion animal market, profiles the companies
leading this sector and assesses prospects for future growth.
Examine in detail market share across the sector with detailed information on
size of business, contribution to total sales, key products and future
prospects for the sector's current market leaders.
Table of Contents
CHAPTER 1 COMPANION ANIMAL HEALTH PROBLEMS
1.1 Infectious diseases
1.1.1 Canine infectious diseases
1.1.1.1 Bordetella bronchiseptica
1.1.1.2 Coronavirus
1.1.1.3 Distemper
1.1.1.4 Hepatitis
1.1.1.5 Influenza
1.1.1.6 Kennel cough
1.1.1.7 Leptospirosis
1.1.1.8 Lyme isease
1.1.1.9 Parvovirus
1.1.1.10 Rabies
1.1.1.11 Feline infectious diseases
1.1.1.12 Feline influenza
1.1.1.13 Chlam ydophila
1.1.1.14 Feline infectious peritonitis
1.1.1.15 Feline leukaemia
1.1.1.16 Panleukopenia
1.1.1.17 Feline immunodeficiency virus
1.1.2 Equine infectious diseases
1.1.2.1 African horse sickness
1.1.2.2 Equine encephalom yelitis
1.1.2.3 Equine infectious anaemia
1.1.2.4 Equine influenza
1.1.2.5 Equine protozoal myeloencephalitis
1.1.2.6 Equine viral arteritis
1.1.2.7 Equine viral rhinopneumonitis
1.1.2.8 Strangles
1.1.2.9 Tetanus
1.1.2.10 West Nile virus
1.2 Parasitic infections
1.2.1 Endoparasites
1.2.1.1 Gastrointestinal nem atodes
1.2.1.2 Heartworms
1.2.1.3 Horse bots
1.2.1.4 Lungworms
1.2.1.5 Protozoa
1.2.1.6 Tapeworms
1.2.2 Ectoparasites
1.2.2.1 Fleas
1.2.2.2 Ticks
1.2.2.3 Mites
1.2.2.4 Lice
1.2.2.5 Flies
1.3 Musculoskeletal problems
1.3.1 Canine osteoarthritis
1.3.2 Equine lameness
1.4 Cardiovascular disease
1.4.1 Cong estive heart failure
1.4.2 Deg enerative valve disease
1.4.3 Cardiom yopathy
1.5 Cancer
1.5.1 Mast cell tumors
CHAPTER 2 COMPANION ANIMAL PRODUCTS
2.1 Introduction
2.2 Anti-infectives
2.2.1 Anti-infective product g roups
2.2.1.1 Am inog lycosides
2.2.1.2 Penicillins
2.2.1.3 Macrolides
2.2.1.4 Lincosamides
2.2.1.5 Tetracyclines
2.2.1.6 Chloramphenicol and derivatives
2.2.1.7 Sulfonamides
2.2.1.8 Cephalosporins
2.2.1.9 Fluoroquinolones
2.2.2 Recent developments
2.2.2.1 New antibiotic active ingredients
Cefpodoxime
Difloxacin
I bafloxacin
Marbofloxacin
Ofloxacin
Orbifloxacin
2.2.3 Future developments
2.2.3.1 Anticipated launch activity
2.3 Antiparasitics
2.3.1 Endoparasiticides
2.3.1.1 Endoparasiticide product groups
I m idazothiazoles
Benzim idazoles
Tetrahydropyrim idines
Macrocyclic lactones
Cyclic depsipeptides
Others
2.3.1.2 Recent developments
Emodepside
Generic penetration
Parasite vaccines
2.3.1.3 Future prospects
2.3.1.4 Ectoparasiticide product groups
Org anophosphates
Carbamates
Form amidines
Pyrethrins and pyrethroids
I nsect growth regulators
Phenylpyrazoles
Neonicotinoids
Recent developments
Fipronil
Imidacloprid
Lufenuron
Nitenpyram
Pyriproxyfen
Future prospects
2.3.1.5 Endectocides
Selam ectin
Quasi-endectocides
Future developments
2.4 Anti-inflammatories
2.4.1 Anti-inflam m atory product g roups
2.4.1.1 Corticosteroids
2.4.1.2 Non-steroidal anti-inflammatory drugs
Established NSAI Dclasses
The coxib NSAI Dsubclass
2.4.2 Recent developments
2.4.2.1 Carprofen
2.4.2.2 Deracoxib
2.4.2.3 Etodolac
2.4.2.4 Firocoxib
2.4.2.5 Meloxicam
2.4.2.6 Tepoxalin
2.4.3 Future prospects
2.5 Other pharm aceuticals
2.5.1 Cardiovascular drugs
2.5.1.1 ACE inhibitors
Enalapril
Benazepril
Ramipril
Imidapril
Alacepril
Temocapril
2.5.1.2 Other cardiovascular drugs
2.5.2 Behavioral therapies
2.5.3 Gastrointestinal drugs
2.5.4 Others
2.5.5 Future prospects
2.5.5.1 Cardiovasculars
2.5.5.2 Behavioral therapies
2.5.5.3 Gastrointestinal drugs
2.5.5.4 Others
2.6 Biologicals
2.6.1 Biolog ical product groups
2.6.1.1 Canine vaccines
2.6.1.2 Feline vaccines
2.6.1.3 Equine vaccines
2.6.1.4 Diag nostics
2.6.2 Recent developments
2.6.2.1 Sm all animal vaccines
2.6.2.2 Equine vaccines
2.6.2.3 Diag nostics
2.6.3 Future prospects
CHAPTER 3 MAJOR NATIONAL MARKETS FOR COMPANION ANIMAL PRODUCTS
3.1 Australia
3.1.1 The Australian market for animal health products
3.1.2 The market for companion animal health products
3.1.3 Companion animal market structure
3.1.4 Companion animal market prospects in Australia
3.2 Brazil
3.2.1 The Brazilian market for animal health products
3.2.2 The market for companion animal health products
3.2.3 Companion animal market structure
3.2.4 Companion animal market prospects in Brazil
3.3 Canada
3.3.1 The Canadian market for animal health products
3.3.2 The market for companion animal products
3.3.3 Structure of the Canadian companion animal market
3.3.4 Companion animal market prospects in Canada
3.4 France
3.4.1 The French market for animal health products
3.4.2 The market for companion animal products
3.4.3 Structure of the French companion animal market
Antiparasitics
Other pharm aceuticals
Biologicals
3.4.4 Companion animal market prospects in France
3.5 Germ any
3.5.1 The Germ an market for animal health products
3.5.2 The market for companion animal health products
3.5.3 Companion animal market structure
3.5.4 Companion animal market prospects in Germ any
3.6 Italy
3.6.1 The Italian market for animal health products
3.6.2 The market for companion animal health products
3.6.3 Companion animal market structure
3.6.4 Companion animal market prospects in Italy
3.7 Japan
3.7.1 The Japanese market for animal health products
3.7.2 The market for companion animal health products
3.7.3 Companion animal market structure
3.7.4 Companion animal market prospects in Japan
3.8 Spain
3.8.1 The Spanish market for animal health products
3.8.2 The market for companion animal health products
3.8.3 Companion animal market structure
3.8.4 Companion animal market prospects in Spain
3.9 United King dom
3.9.1 The UK market for animal health products
3.9.2 The market for companion animal products
3.9.3 Structure of the companion animal products market
Antiparasitics
Other pharm aceuticals
Biologicals
3.9.4 Companion animal market prospects in the UK
3.10 United States of Am erica
3.10.1 The US market for animal health products
3.10.2 The market for companion animal products
3.10.3 Companion animal market structure
Antiparasitics
Other pharm aceuticals
Biologicals
3.10.4 Companion animal market prospects in the US
New products and patent expiries
CHAPTER 4 THE GLOBAL MARKET FOR COMPANION ANIMAL PRODUCTS
4.1 The g lobal market for animal health products
4.2 The g lobal market for companion animal health products
4.3 Companion animal product sales by reg ion
4.4 Major national markets for companion animal products
4.5 Market drivers and constraints
4.5.1 Companion animal populations
Developed countries
Developing countries
4.5.2 Econom ic, social and demographic trends
Economic growth
Developed countries
Developing countries
Social and demographic trends
4.5.3 New products and technologies
Market impact
4.5.4 Prom otion and marketing techniques
4.5.5 Companion animal health and disease trends
4.5.6 Patent expiries and generic penetration
Ivermectin
Other recent generic targets
Future generic targets
4.5.7 Product safety issues
ProHeart 6
NSAI Ds
Lessons for the industry
4.5.8 Regulatory factors
Market impact
4.5.9 Companion animal health insurance
4.6 Future growth of the companion animal products market
